Alexion Pharma (ALXN) Tops Q4 EPS by 32c, FY EPS Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Reports Fourth Quarter and Full Year 2018 Results
February 4, 2019 6:30 AM EST4Q18 total revenues of $1,128.8 million, a 24 percent increase over 4Q17 and a 30 percent volume increase 4Q18 GAAP diluted EPS of $(0.20); non-GAAP diluted EPS of $2.14 2019 guidance: revenue $4,625 to $4,700 million; GAAP diluted EPS of $6.14 to $7.26; non-GAAP diluted EPS of $9.10 to $9.30 SOLIRIS® (eculizumab) for Generalized Myasthenia Gravis (gMG) best Alexion launch in first year following regulatory approval U.S. launch underway for ULTOMIRIS (ravulizumab-cwvz) in adults with paroxysmal nocturnal hemoglobinuria (PNH); EU and Japanese applications under review... More
